PDX model details
| PDX ID |
201.2A Cx |
| Host Strain(and Source) |
NSG Source: Monash University |
| Host Strain Immune system Humanized |
NO |
| Host Type |
Castrate |
| Graft Site |
Subcutaneous |
Current Generation (* indicates number of generations grown in Castrate host) |
26 (19*) |
| Average PDX Generation Time (days +/- SEM) |
44 ± 2 |
| Tumour preparation |
Tumor solid |
| Tumour Characterization Technology |
Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin |
Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed |
Routine QA every 2-3 passages |
| Associated meta data |
| PDX model availability |
Yes (fixed, frozen or cryopreserved tissue) |
| Governance restriction for distribution |
Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID |
34413304; 30049486 |
| |
|
| Markers |
201.2A Cx |
| AR |
N |
| PSA |
N |
| PSMA |
N |
| NE |
Y |
| ERG |
N |
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.
This table displays curated CNVs
|
PDX ID
|
Gene Symbol
|
CNV Log2
|
CNV Copy
|
CNV Call
|
Experiments name
|
Platform
|
Reference genome
|
| 201.2A Cx |
RB1 |
-26.4693 |
0.0000000215 |
homdel
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
PTEN |
-14.1286 |
0.00011166 |
homdel
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
PTEN |
-1.24069 |
0.84634 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
SUFU |
-1.24069 |
0.84634 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
CUL3 |
-1.0749 |
0.949408 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
CDKN1B |
-1.0658 |
0.955415 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
CHD1 |
-1.05096 |
0.965294 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
APC |
-1.05096 |
0.965294 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
SMARCAD1 |
-1.01026 |
0.992914 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
CDKN2A |
-1.00407 |
0.997183 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
USP28 |
-1.00272 |
0.998116 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
SMAD2 |
-1.00125 |
0.999134 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
MBD1 |
-1.00125 |
0.999134 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
TCERG1 |
-0.999305 |
1.00048 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
ARID4A |
-0.99595 |
1.00281 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
ZNRF3 |
-0.938991 |
1.0432 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
ERF |
-0.918781 |
1.05791 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
AKT1 |
-0.91813 |
1.05839 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
TP53 |
-0.845146 |
1.11331 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
PIK3CB |
0.505852 |
2.83992 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
CHD7 |
0.558955 |
2.9464 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 201.2A Cx |
MYC |
0.960313 |
3.89146 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
Clinical Information
| Sample Number |
201.2A |
| Sample Site |
Lung |
| Sample source |
Autopsy |
| Pathology Tumour Diagnosis |
Adenocarcinoma |
| Gleason Score |
None |
| Primary Gleason Score |
None |
| Secondary Gleason Score |
None |
| Tertiary Gleason Score |
None |
| ISUP Grade Group |
|
| Tumour Grade |
|
| D'Amico Risk Classification |
|
| Tumour Volume (in cc) |
0.0 |
| Treatment Prior to Specimen Collection |
ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide |
| |
|
Patient Information
| Patient Number |
201 |
| Sex |
Male |
| Diagnosis |
Prostate Cancer |
| PSA at diagnosis (ng/mL) |
NA |
| Consent to share data |
|
| |
|
This heatmap displays the mutations of curated sequence variants.
Download
This table displays curated sequence variants
|
PDX ID
|
Gene Symbol
|
Depth
|
ALT_FREQ
|
Consequence
|
Exon
|
GnomAD_AF
|
CADD_PHRED
|
Clinvar_clnsig
|
Platform
|
Experiments Name
|
Reference
|
Library Type
|
Instrument Type
|
| 201.2A Cx |
CTNNB1 |
474 |
1.0 |
missense_variant |
'3/15 |
. |
29.9 |
Pathogenic/Likely_pathogenic,_other
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 201.2A Cx |
AR |
255 |
1.0 |
missense_variant |
'8/8 |
. |
25.3 |
Pathogenic
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 201.2A Cx |
TP53 |
258 |
1.0 |
missense_variant |
'8/11 |
1.22E-05 |
25.3 |
Conflicting_interpretations_of_pathogenicity
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 201.2A Cx |
ZMYM3 |
184 |
0.98 |
frameshift_variant |
'8/25 |
. |
. |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 201.2A Cx |
MUTYH |
608 |
0.5 |
missense_variant |
'13/16 |
0.0007924 |
20.7 |
Conflicting_interpretations_of_pathogenicity
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 201.2A Cx |
CACNA1H |
585 |
0.5 |
missense_variant |
'9/35 |
8.90E-05 |
5.716 |
Uncertain_significance
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 201.2A Cx |
MSH2 |
280 |
0.49 |
missense_variant |
'16/16 |
6.12E-05 |
27.7 |
Uncertain_significance
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 201.2A Cx |
ARID1A |
623 |
0.32 |
frameshift_variant |
'3/20 |
. |
. |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
No information in Drug dosing Table